[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360689-105":59,"doc-detail-360689-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","upregulated-circular-rnas-in-gastric-cancer-target-identification-and-tools-for-therapeutic-intervention-review","Upregulated Circular RNAs in Gastric Cancer - Target Identification and Tools for Therapeutic Intervention - Review","","Literature survey (PubMed) identifies upregulated circular RNAs (circRNAs) implicated in gastric cancer pathogenesis and dissemination. The review concentrates on circRNAs that upregulate target classes or physiological processes including transmembrane receptors, secreted proteins, RNA metabolism and processing, ubiquitination, WNT signalling, ferroptosis pathways, and druggable enzymes. It validates circRNAs as target-identification tools by highlighting candidates linked to approved drugs, such as VEGF-A and PD-L1, and discusses technical considerations for inhibiting the implicated targets and corresponding circRNAs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/upregulated-circular-rnas-in-gastric-cancer-target-identification-and-tools-for-therapeutic-intervention-review/360689/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/upregulated-circular-rnas-in-gastric-cancer-target-identification-and-tools-for-therapeutic-intervention-review/360689.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which circRNA-related target classes are emphasized for gastric cancer?","Question",{"text":112,"@type":113},"The review emphasizes circRNAs that upregulate transmembrane receptors, secreted proteins, RNA metabolism and processing, ubiquitination, WNT signalling, ferroptosis-related pathways, and druggable enzymes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are circRNAs linked to approved therapeutic agents in gastric cancer?",{"text":117,"@type":113},"CircRNAs upregulating targets for approved GC drugs, including VEGF-A and PD-L1, are identified to validate circRNAs as tools for target identification.",{"name":119,"@type":110,"acceptedAnswer":120},"What technical issues does the review discuss for therapeutic intervention?",{"text":121,"@type":113},"The review discusses technical issues involved in inhibiting the identified targets and their corresponding circular RNAs, including considerations relevant to the proposed intervention strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360689,1790167225,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","doi: 10.21873/cgp.20590  \nReview  \nUpregulated Circular RNAs in Gastric Cancer: Target Identification and Tools for Therapeutic Intervention  \nSAMUELE GRAZIANO1, BARBARA HÖLLBACHER1 and ULRICH H. WEIDLE2  \n1Computational Sciences Center of Excellence, F. Hoffmann-La Roche Ltd., Basel, Switzerland;  \n2 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany  \nAbstract  \nSurveying the literature (PubMed), we have identified upregulated circular RNAs involved in pathogenesis and dissemination of gastric cancer. We have focused on circRNAs that upregulate the following target classes or physiological processes: transmembrane receptors, secreted proteins, RNA metabolism and processing, ubiquitination, WNT signalling, ferroptosis and druggable enzymes. Circular RNAs upregulating targets for approved drugs in GC, such as vascular endothelial growth factor A (VEGF-A) and programmed death-ligand 1 (PD-L1), were identified, validating circRNAs as tools for target identification. We highlight targets and target classes that are frequently affected by circRNAs such as solute carrier (SLC) proteins, subtypes of heterogeneous nuclear RNA (hnRNA), ubiquitin-specific proteases (USPs) and targets related to inhibition offerroptosis. We also highlight druggable enzymes as targets. We discuss technical issues for inhibition of the identified targets and their corresponding circular RNAs.  \nKeywords: Antisense oligonucleotides, ASO, inhibition of circular RNAs, circRNAs, short hairpin RNA, shRNA, small interfering RNA, siRNA, therapeutic targets, tumor growth and metastasis, xenograft models, review.  \nIntroduction  \nGastric cancer (GC) is thought to arise from a combination of environmental factors and the accumulation of specific genetic alterations (1). The annual death toll from GC is approximately 800,000 worldwide (1). China and Japan have the highest incidence accounting for 30% of all GC cases (1).  \nOver 90% of GC cases can be classified as glandular adenocarcinomas of intestinal type and diffuse-type tumors. Rarer subtypes are gastrointestinal stromal cancer (GIST), lymphomas and carcinoid (neuroendocrine) tumors (2, 3). Four molecular subtypes have been identified: Epstein-Barr Virus (EBV), microsatellite instability (MSI), chromosomal instability (CIN) and genomically stable (GS) (4). Three  \nUlrich H. Weidle, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.  \nTelman:-4L9a88Ro5c66028he Ltd0, 1B,eas-mel,ail: weidle49@tSwitzerland Te-lo: li4n1e7. d9e2a8n7d2Ba00r2b, aer-a Hömaill:lbacherbarbar,aCohmputaoellbactihoenral@SrcieochnececsoCenterm of Excellence,  \nReceived April 21, 2026 | Revised May 20, 2026 | Accepted May 26, 2026  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Published by the International Institute of Anticancer Research.  \npercent of GC cases are inherited due to germline mutations in the E-cadherin gene (5). Despite the approval of several chemotherapy-based combination regimens and monoclonal antibodies (mAbs), advanced GC is associated with a poor prognosis, corresponding to a median survival time of 12-15 months (6-10). Approved therapeutic agents include Ramucirumab [inhibiting vascular endothelial growth factor receptor 2 (VEGFR2)], immune checkpointtargeting mAbs such as pembrolizumab [inhibiting programmed cell death protein 1 (PD1)], nivolumab (inhibiting PD1), as well asTrastuzumab [inhibiting human epidermal growth factor receptor 2 (HER2)] and Enhertu, atrastuzumab-drug conjugate for HER2-positive GCs. Recently, the FDA has approved Zolbetuximab, a mAb directed against tight-junction protein claudin 18.2 (CLDN18.2) for treatment of GC and gastro-esophageal junctional cancer (GEJ) in combination with chemotherapy (11, 12). Small molecules inhibitin","cbCaioxkmXmphkez","https://ap.wps.com/l/cbCaioxkmXmphkez","pdf",2397665,"English","# Abstract\n# Keywords\n# Introduction\n## Background and epidemiology of gastric cancer\n# Circular RNA\n## Classification and properties of circRNAs\n## Functions and roles in cancer","[{\"question\":\"Which circRNA-related target classes are emphasized for gastric cancer?\",\"answer\":\"The review emphasizes circRNAs that upregulate transmembrane receptors, secreted proteins, RNA metabolism and processing, ubiquitination, WNT signalling, ferroptosis-related pathways, and druggable enzymes.\"},{\"question\":\"How are circRNAs linked to approved therapeutic agents in gastric cancer?\",\"answer\":\"CircRNAs upregulating targets for approved GC drugs, including VEGF-A and PD-L1, are identified to validate circRNAs as tools for target identification.\"},{\"question\":\"What technical issues does the review discuss for therapeutic intervention?\",\"answer\":\"The review discusses technical issues involved in inhibiting the identified targets and their corresponding circular RNAs, including considerations relevant to the proposed intervention strategies.\"}]","Upregulated Circular RNAs in Gastric Cancer - Target Identification and Tools for Therapeutic Intervention - Review | PDF",1790141172,76,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce5050e50fa64becfa694fc0c690e56c.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98bdf8a2261eeac86f589851b78c1c4e.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cd92b9cb5db65864f26086da10dbbe8.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c59f01998b1787602bf1d925949e314.webp",980,1306]